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RESUMO 
Introdução: Apesar do avanço no conhecimento fisiopatológico da nefrolitíase, a avaliação do risco individual de formação e 
recorrência de cálculos renais por mensuração de fatores de risco na urina de 24 horas é muitas vezes difícil. Nosso objetivo é avaliar fatores 
de risco urinários associados à nefrolitíase, particularmente citraturia e a proporção cálcio/citrato em pacientes com cálculos renais recorrentes 
e naqueles sem litíase urinária. Método: 103 pacientes com nefrolitíase recorrente (30 homens e 73 mulheres) e 32 pacientes sem doença 
(11 homens e 21 mulheres) foram estudados retrospectivamente. Dados clínicos e laboratoriais foram colhidos de todos os pacientes. 
Resultados: Não houve diferença de idade entre os grupos (44,4±11,8 anos vs 43,3±17 anos). Na urina, houve aumento de volume, cálcio 
(189,6±98,7 vs. 150,7±107,3, p=0,029), sódio e oxalato (33,7±28,2 vs. 22,2±15,3, p=0,041) no grupo dos litiásicos, comparados ao grupo 
controle. A excreção urinária de ácido úrico e citrato foi similar entre os grupos, sem diferenças significativas. Houve correlação positiva entre a 
excreção de cálcio e citrato na urina dos pacientes litiásicos (r=0,41, p<0,001). Não foi possível utilizar a proporção cálcio/citrato para 
diferenciar os grupos, pois diferenças não foram encontradas. Conclusão: Em pacientes com nefrolitíase recorrente, os fatores de risco em 
urina de 24 horas necessitam ser interpretados como variáveis contínuas, e não intervaladas. Estudos prospectivos são necessários para 
determinar valores normais diários de citraturia e para avaliar o papel da hipocitraturia isolada na incidência, prevalência e curso clínico na 
formação de cálculos renais. 
Palavras-chave: citrato; nefrolitíase; cálculo renal; hipocitraturia. 
 
ABSTRACT 
Introduction: Despite the progress in the pathogenesis of nephrolithiasis, the individual risk assessment of formation and 
recurrence of kidney stones by measuring risk factors in 24-hour urine is often difficult. Our objective was to evaluate urinary risk factors 
associated with nephrolithiasis, particularly citraturia and the calcium/citrate ratio in recurrent kidney stones formers and in subjects without 
nephrolithiasis. Methods: 103 kidney stone formers (30 men and 73 women) and 32 non-stone subjects (11 men and 21 women) were 
retrospective studied. Clinical and laboratory data were collected from every subject. Results: There was no difference in age between the 
groups (44.4±11.8 years and 43.3±17 years). In urine, volume, calcium (189.6±98.7 vs. 150.7±107.3, p=0.029), sodium and oxalate 
(33.7±28.2 vs. 22.2±15.3, p=0.041) were higher in kidney stones when compared to control subjects. Urinary excretion of uric acid and citrate 
was similar in both groups, with no significant differences. For the cohort of stone formers patients, but not for healthy subjects, there was a 
positive correlation between calcium and citrate excretion in urine (r=0.41, p<0.001). When utilizing the calcium/citrate ratio to differentiate 
stone and non-stone formers subjects, we could not find any difference. Conclusion: For the kidney stone formers, the assessment of risk 
factors by 24-hour urine needs to be categorized as continuous and not as interval variables. Prospective studies are necessary to determine 
the normal range of daily citraturia and to evaluate the role of isolated hypocitraturia in the incidence, prevalence and clinical course of kidney 
stone formation. 
Keywords: citrate; nephrolithiasis; kidney stone; hypocitraturia. 
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INTRODUCTION  
	  
The occurrence of urolithiasis is high and is 
increasing worldwide. The lifetime risk of symptomatic 
kidney stones is approximately 13% in men and 7% in 
women1. In addition, its recurrence rate is also elevated. 
Once diagnosed, 50% of adult urolithiasis patients recurred 
in 5–10 years and 75% in 20 years2. 
Despite the progress in the pathogenesis of 
nephrolithiasis, the precise assessment of the risk 
of calcium oxalate urinary stones and the detection of 
patients at risk of recurrent stones are often 
difficult3. Hypercalciuria, the most common metabolic 
abnormality found in calcium stone formers, even being 
often familial and idiopathic, is mainly influenced by diet4. 
Hypercalciuria increases urine supersaturation and 
promotes crystal formation and growth. Reducing urine 
calcium with thiazide diuretics decreases the number of 
stone recurrences and stone formation rate5. 
Urinary citrate also plays an important role in 
reducing the formation and recurrence of kidney stones by 
chelating calcium, inhibiting spontaneous nucleation and 
aggregation of oxalate crystals6 and interacting with Tamm-
Horsfall protein to inhibit calcium oxalate crystallization7. 
Idiopathic hypocitraturia, usually defined as urinary citrate 
excretion less than 320 mg/day for adults, is a common 
metabolic abnormality occurring in 20% to 60% of stone 
formers3,8. Citrate excretion is under influence of multiple 
factors and thus may influence by different ways the 
formation of kidney stones8. 
Analysis of risk factors for nephrolithiasis by 24-
hour urine is essential to prevent kidney stone recurrence. 
However, some publications that studied large cohort of 
patients found that traditional values need to be 
reassessed, as a substantial proportion of controls would 
be defined as “abnormal”. Furthermore, the association of 
several urinary parameters with risk of stone formation 
may be continuous rather than dichotomous9. Other 
authors suggested indexes (for example, the 
calcium/citrate ratio in urine) to improve the clinical 
diagnosis accuracy along with the criteria currently in use 
10,11. 
Our objective was to evaluate the urinary 
excretion of common risk factors associated with 
nephrolithiasis, with particular attention to citraturia and to 
the calcium/citrate ratio in recurrent kidney stones formers 
and in subjects without nephrolithiasis.	  
PATIENTS AND METHODS  
	  
We conducted a retrospective study from 
recurrent stone-formers who attended our Nephrolithiasis 
Clinic. The diagnosis of recurrent urolithiasis was based on 
at least two episodes of spontaneous or surgical 
elimination of a stone or demonstration of more than one 
Rx-opaque kidney stone.  
No patient had any systemic or renal disease as 
cause or consequence of stones and all had normal blood 
calcium. Sarcoidosis, vitamin D excess, malignant 
neoplasm, renal tubular acidosis, calcium or citrate 
supplement use at the time of the study evaluation was 
excluded. A control group of non-stone forming and without 
any known medical disorder was selected at the same time 
and in the age range of the first consultation of the case 
patient, in a proportion of ~1:3, respectively.  
 Data on each patient was collected, including age 
at first visit, gender, body mass index (BMI) and blood 
pressure (BP). Using our usual laboratory protocol [12], 
blood samples were taken after an overnight fasting to 
measure serum creatinine and calcium. 24-hour urine 
samples were collected with an interval of at least 30 days 
after ESWL or an acute pain episode, with patients in their 
usual diet. The following parameters were analyzed: pH, 
volume, creatinine, calcium, sodium, oxalate, citrate, and 
uric acid. Creatinine clearance was calculated as the ratio 
of 24-hour creatinine excretion to the serum creatinine and 
calcium/citrate ratio by the ratio of urine calcium to citrate 
in mg/day. The urinary parameters represent the average 
of two or three 24-hour urine collections for each subject. 
Normally distributed continuous data were 
expressed as mean ± SD and inter-group differences were 
assessed by independent Student’s t test. Skewed 
continuous data were reported as median and interquartile 
range (25-75 percentiles), and differences between the 
groups were evaluated by the Mann-Whitney rank-sum test. 
Categorical data were assessed by Yates corrected chi-
square test. Correlations between urinary parameters were 
assessed using simple linear regression. A multivariable 
linear regression model was used to evaluate the citrate 
excretion after adjusting for other variables. Statistical 
analysis were performed with Sigmastat software version 
3.5 (Systat Software Inc, San Jose, CA) for data analysis. A 
p value of less than 0.05 was considered statistically 
significant and all reported p values are two-tailed.  
The study protocol was approved by the local 
ethics committee. 
 
RESULTS  
	  
A total of 103 kidney stone formers (30 men and 
73 women) and 32 non-stone subjects (11 men and 21 
women) were included in this study. The mean age for the 
urolithiasis group was 44.4±11.8 years and 43.3±17 years 
for the control subjects (p=0.656). Systolic (122±13 and 
119±13 mmHg) and diastolic (82±10 and 77±12 mmHg) 
BP were within normal ranges for kidney stone formers and 
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controls, respectively. Both groups were categorized as 
overweight according to the mean BMI. However, subjects 
without kidney stones had a higher BMI (27.8±5.7) than 
stone formers (25.4±5, p<0.025). 
Creatinine clearance, serum calcium and 24-hour 
urine collection are listed in Table. Glomerular filtration 
rate, as estimated by creatinine clearance, was similar 
between groups. Serum calcium has higher in the kidney 
stone formers, but within the reference range values (8-10 
mg/dL). In urine, volume, calcium, sodium and oxalate 
were higher in kidney stones when compared to control 
subjects. Forty percent of stone formers (41/103) had 
urinary calcium levels higher than 200 mg/day compared 
with 15% (5/32) of controls (χ2 - 0.09). Urinary excretion of 
uric acid and citrate was similar in both groups, with no 
significant differences (Table). A total of 29% stone formers 
and 32% of controls subjects had urinary citrate levels less 
than 320 mg/day. Female stone formers had greater 
citraturia compared with men with nephrolithiasis (median 
500.75 vs. 351.3 mg/day, respectively, p<0.03). When 
utilizing the calcium/citrate ratio to distinguish stone and 
non-stone formers we could not find any significant 
difference (p=0.27, Figure 1A). The same was true when 
we analyzed the calcium/citrate ratio among men or 
women with or without kidney stones (Figure1B). 
For the entire cohort of kidney stone patients, but 
not for the subjects without kidney stones, there was a 
positive correlation between calcium and citrate excretion 
in urine (r=0.41, p<0.001, Figure 2). In this group, multiple 
linear regression was performed using urinary volume, 
sodium, oxalate and calcium as significant variables with 
citrate excretion as the dependent variable. Only calcium 
was likely to be independently related to citrate excretion 
(p<0.02). 
 
 
DISCUSSION  
	  
About 80% of kidney stones are composed of 
calcium oxalate with variable amounts of calcium 
phosphate. Evaluation and medical management of 
recurrent kidney stone formers is cost-effective and can 
help decrease further recurrence13. Metabolic 
abnormalities, as identified by 24-hour urine collection, are 
found in the majority of patients.  
In this study, urinary volume and excretion of 
calcium, sodium and oxalate were higher in this select 
population of recurrent kidney stone formers when 
compared to healthy, control subjects. 
Imbalances between excretion of calcium, 
oxalate, and water create supersaturation. Idiopathic 
hypercalciuria is the most important metabolic abnormality 
found in patients with recurrent calcium stones. It is usually 
a familial disorder, although strongly influenced by diet5. 
Hypercalciuria often is defined as an excretion of more 
than >300 mg/day for men and >250 mg/day for women4 
or sometimes as greater than 200 mg daily with no gender 
differences14. Our stone formers group excreted more 
calcium compared to controls (189.6±98.7 
vs.150.7±107.3 mg/day, p=0.029) and 40% of them had 
urinary calcium levels higher than 200 mg/day compared 
 Stone Formers (n=103) Controls (n=32) p value 
GFR** (ml/min) 123 ± 34.87 123.38 ± 44.97 0.347 
Serum Calcium (mg/dl)  9.4 (8.9 – 9.9) 9.0 (8.8 – 9.3) 0.008 
Volume (ml/24 hr)  1920 ± 690 1550 ± 584 0.012 
pH 5.96 ± 0.65 5.72 ± 0.57 0.238 
Creatinine (mg/24 hr) 1490 ± 1097 1487 ± 618 0.995 
Calcium (mg/24 hr) 189.6 ± 98.7 150.7 ± 107.3 0.029 
Sodium (meq/24 hr) 160.8 (122.37 –  221.75) 116.5 (79 – 172.80) 0.013 
Oxalate (mg/24 hr) 33.7 ± 28.2 22.2 ± 15.3 0.041 
Citrate (mg/24 hr) 579.4 ± 423.5 542.1 ± 381.3 0.828 
Uric Acid (mg/24 hr)  484.16 ± 193.29 508.57 ± 266.01 0.922 
* Data showed as mean ± SD or median (25-75%); **GFR: Glomerular filtration rate as estimated by Creatinine Clearance 
 
Table – Serum and 24 hour-ur ine biochemistry* 
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with 15% of controls (χ2 - 0.09). We believe that urinary 
calcium is continuously distributed and it is likely that 
values bellow those cited before are still relevant and 
should not be ignored15. Pak et al., by receiver operating 
characteristic curve analysis showed that the optimal cutoff 
point for calciuria was 172 mg/day, even if the patients 
were in a restricted diet16. In one study with large cohorts 
of patients, the relative risk of stone formation was 
increased more than 4 times with urine calcium ≥200 
mg/day. Additionally, in this study the percentage of 
hypercalciuria in subjects without kidney stones was similar 
to our findings, ~15% 9.  
 
Figure 1A -  Calcium/citrate ratio in stone formers and 
control subjects 
 
Three findings of our work are relevant and 
related to pathogenesis of hypercalciuria and deserve a 
brief comment. First, we found a higher urinary volume in 
stone formers compared to control subjects (1920±690 
vs.1550±584 ml/day, p=0.012). Although the stone 
formers were selected for this work after the first or second 
visit to our clinic, the most plausible explanation for this 
finding is the so called stone clinic effect, the act of 
encouraging a high intake of fluid and diet counseling in 
the treatment of kidney stone disease 17,18. Another 
hypothesis, albeit not clinically tested, is that higher urinary 
calcium diminishes urinary concentration as an adaption to 
prevent calcium stone disease. This assumption is based in 
animal studies that found reductions of medullary 
collecting duct water permeability with higher luminal 
calcium concentrations due to activation of calcium 
sensing receptors19. Second, both groups showed elevated 
24-hour urinary sodium excretion, with higher levels in the 
kidney stone subjects (median 160.8 vs. 116.5, p= 0.013). 
A high salt intake increases stone risk by reducing tubular 
calcium reabsorption and increasing urinary calcium, 
decreasing citraturia and elevating urinary saturation of 
monosodium urate14. Finally, excretion of oxalate was 
significant higher in stone forming group, although in levels 
below the commonly accepted definition of hyperoxaluria, 
i.e. greater than 40 mg daily (33.7±28.2 vs. 22.2±15.3, 
p=0.041)4. In a cross-sectional study of 3348 stone 
forming and non-stone-forming participants in the Health 
Professionals Follow-up Study (men), the Nurses' Health 
Study (older women), and the Nurses' Health Study II 
(younger women), Taylor and Curhan found similar median 
urinary oxalate of 39 mg/day in men, 27 mg/day in older 
women, and 26 mg/day in younger women 20. In normal 
people, the impact of dietary oxalate on urinary oxalate 
appears to be small. The amount of oxalate available for 
absorption throughout the intestine is highly dependent on 
the state of oxalate in the food ingested, and in the 
intestinal contents at each section of the intestinal tract 
since only the soluble form of oxalate can be absorbed 21.   
In our point of view, the most relevant topic to be 
discussed in this work is the failure of urinary citrate to 
differentiate stone formers from the control group and the 
high percentage of hypocitraturia, defined as <320 
mg/day, in healthy subjects. Neither daily citraturia (579.4 
± 423.5 vs. 542.1 ± 381.3, p=0.828), the percentage of 
hypocitraturia, (29% vs. 32%, χ2 =0.9), or the 
calcium/citrate ratio (Figure 1B) were different between the 
groups. We could only demonstrated that female stone 
formers had greater citraturia compared with men with 
nephrolithiasis [median 500.75 vs. 351.3 mg/day, 
respectively, p<0.03)] and that stone formers showed a 
positive correlation between calcium and citrate excretion 
in urine (r=0.41, p<0.001, Figure 2).  
 
Figure 1B – Calcium/citrate ratio between men and 
women with or without kidney stones.  
 
It is well known that urinary citrate inhibits 
calcium oxalate stone formation by lowering urinary 
calcium and by preventing agglomeration and growth 
through its ability to bind to the crystal’s surface8. Citrate 
also improves inhibitory activity of Tamm-Horsfall protein, 
leading to formation of smaller and less aggregated 
crystals7. Additionally, randomized trials have shown 
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significant reductions in stone recurrence among 
hypocitraturic patients treated with potassium citrate 4. 
However, few studies compare citrate excretion 
between stone formers and healthy controls. In a work with 
a large number of subjects, the authors found no gender or 
case-control differences in citraturia. The percentage of 
hypocitraturia (<320 mg/day) varied from 3 to 9% in the 
control group and from 5 to 11% in the kidney stone 
formers and citraturia was not inversely associated with the 
risk of stone formation 9. Other works also found overlap in 
the urinary citrate excretion between normal subjects and 
stone-formers 22, similar values between normal subjects 
and first time stone formers, but not recurrent calcium 
stone formers23 and even findings of 70% of kidney stone 
formers and 72% of controls presenting with citraturia 
<320 mg/day 24. There are also divergent findings when 
different works considered the balance between calcium 
and citrate (the calcium/citrate ratio) and not the absolute 
excretion of citrate in mg/day. Some studies considered 
the index useful 10,11, others could not find any difference 
between stone formers and controls25.  
 
Figure 2 – Posit ive relationship between calcium and 
citrate urine excretion rate in stone formers group (r= 
0.41, p<0.001). 
 
A number of aspects can influence citraturia and 
partially explain the large variation of hypocitraturia 
prevalence reported in the literature. Determination of 
citrate levels in urine can be affected by factors such as 
intra-individual variation26 or even acidification of the 
samples27. Laboratories can use different methods to 
measure citrate (for example, high-performance liquid 
chromatography (HPLC) or enzymatic citrate lyase-based) 
and results can be difficult to compare 28,29.  Reference 
values of citraturia can vary substantially, ranging from a 
cutoff of 115 mg/day in males and 200 mg/day in 
females30 to >450 mg/day for males and >550 mg/day for 
females4. In addition, considering the complex nature of 
urinary citrate metabolism, genetic influences31,32 and 
diverse dietary and medical conditions can influence 
excretion of citrate 2,6,8.  
Limitations of this work include the small sample 
size and its retrospective design. It is clear that we need 
more prospective studies to determine the normal range of 
daily citraturia and to evaluate the role of hypocitraturia in 
the incidence, prevalence and clinical course of kidney 
stone formation. 
In summary, the present study showed that 
excretion of calcium, sodium and oxalate were higher in 
recurrent kidney stone formers when compared to healthy 
subjects and that neither the usual definition of 
hypocitraturia (>320 mg/day) or the calcium/citrate ratio 
were able to differentiate both groups.	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